Cancer Research Cancer Epigenetics Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tian, F.
Right arrow Articles by Roberts, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tian, F.
Right arrow Articles by Roberts, A. B.
[Cancer Research 64, 4523-4530, July 1, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Smad-Binding Defective Mutant of Transforming Growth Factor ß Type I Receptor Enhances Tumorigenesis but Suppresses Metastasis of Breast Cancer Cell Lines

Fang Tian1, Stacey DaCosta Byfield1, W. Tony Parks3, Christina H. Stuelten1, Deepa Nemani1, Ying E. Zhang2 and Anita B. Roberts1

Laboratory of 1 Cell Regulation and Carcinogenesis and 2 Cellular and Molecular Biology, National Cancer Institute, Bethesda, Maryland, and 3 Department of Pathology, University of Washington, Seattle, Washington

The role of transforming growth factor ß (TGF-ß) in carcinogenesis is complex, with tumor suppressor and pro-oncogenic activities depending on the particular tumor cell and its stage in malignant progression. We previously have demonstrated in breast cancer cell lines that Smad2/3 signaling played a dominant role in mediating tumor suppressor effects on well-differentiated breast cancer cell lines grown as xenografts and prometastatic effects on a more invasive, metastatic cell line. Our present data based on selective interference with activation of endogenous Smad2 and Smad3 by stable expression of a mutant form of the TGF-ß type I receptor (RImL45) unable to bind Smad2/3 but with a functional kinase again show that reduction in Smad2/3 signaling by expression of RImL45 enhanced the malignancy of xenografted tumors of the well-differentiated MCF10A-derived tumor cell line MCF10CA1h, resulting in formation of larger tumors with a higher proliferative index and more malignant histologic features. In contrast, expression of RImL45 in the more aggressive MCF10CA1a cell line strongly suppressed formation of lung metastases following tail vein injection. These results suggest a causal, dominant role for the endogenous Smad2/3 signaling pathway in the tumor suppressor and prometastatic activities of TGF-ß in these cells. Using an in vitro assay, we further show that non-Smad signaling pathways, including p38 and c-Jun NH2-terminal kinase, cooperate with TGF-ß/Smads in enhancing migration of metastatic MCF10CA1a cells, but that, although necessary for migration, these other pathways are not sufficient for metastasis.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
P. Wang, Z. Chen, Z.-Q. Meng, J. Fan, J.-M. Luo, W. Liang, J.-H. Lin, Z.-H. Zhou, H. Chen, K. Wang, et al.
Dual role of Ski in pancreatic cancer cells: tumor-promoting versus metastasis-suppressive function
Carcinogenesis, September 1, 2009; 30(9): 1497 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. J. You, T. How, and G. C. Blobe
The type III transforming growth factor-{beta} receptor negatively regulates nuclear factor kappa B signaling through its interaction with {beta}-arrestin2
Carcinogenesis, August 1, 2009; 30(8): 1281 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Melisi, S. Ishiyama, G. M. Sclabas, J. B. Fleming, Q. Xia, G. Tortora, J. L. Abbruzzese, and P. J. Chiao
LY2109761, a novel transforming growth factor {beta} receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Mol. Cancer Ther., April 1, 2008; 7(4): 829 - 840.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. S. Rosman, S. Phukan, C.-C. Huang, and B. Pasche
TGFBR1*6A Enhances the Migration and Invasion of MCF-7 Breast Cancer Cells through RhoA Activation
Cancer Res., March 1, 2008; 68(5): 1319 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. J. You, M. W. Bruinsma, T. How, J. H. Ostrander, and G. C. Blobe
The type III TGF- receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation
Carcinogenesis, December 1, 2007; 28(12): 2491 - 2500.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
B. C. Willis and Z. Borok
TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease
Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L525 - L534.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Belmadani, J. Bernal, C.-C. Wei, M. A. Pallero, L. Dell'Italia, J. E. Murphy-Ullrich, and K. H. Berecek
A Thrombospondin-1 Antagonist of Transforming Growth Factor-{beta} Activation Blocks Cardiomyopathy in Rats with Diabetes and Elevated Angiotensin II
Am. J. Pathol., September 1, 2007; 171(3): 777 - 789.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Galliher and W. P. Schiemann
Src Phosphorylates Tyr284 in TGF-{beta} Type II Receptor and Regulates TGF-{beta} Stimulation of p38 MAPK during Breast Cancer Cell Proliferation and Invasion
Cancer Res., April 15, 2007; 67(8): 3752 - 3758.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
P. C. Gray, G. Shani, K. Aung, J. Kelber, and W. Vale
Cripto Binds Transforming Growth Factor {beta} (TGF-{beta}) and Inhibits TGF-{beta} Signaling
Mol. Cell. Biol., December 15, 2006; 26(24): 9268 - 9278.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Biswas, T. L. Criswell, S. E. Wang, and C. L. Arteaga
Inhibition of Transforming Growth Factor-{beta} Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy.
Clin. Cancer Res., July 15, 2006; 12(14): 4142 - 4146.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Bandyopadhyay, J. K. Agyin, L. Wang, Y. Tang, X. Lei, B. M. Story, J. E. Cornell, B. H. Pollock, G. R. Mundy, and L.-Z. Sun
Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-{beta} Type I Receptor Kinase Inhibitor.
Cancer Res., July 1, 2006; 66(13): 6714 - 6721.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Kang, W. He, S. Tulley, G. P. Gupta, I. Serganova, C.-R. Chen, K. Manova-Todorova, R. Blasberg, W. L. Gerald, and J. Massague
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway
PNAS, September 27, 2005; 102(39): 13909 - 13914.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E. T. Keller
Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism
Cancer Res., September 15, 2005; 65(18): 8274 - 8285.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. Moustakas and C.-H. Heldin
Non-Smad TGF-{beta} signals
J. Cell Sci., August 15, 2005; 118(16): 3573 - 3584.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.